Published July 2026
We are pleased to share our Q2 2026 update on the pharmaceutical commercialization landscape. The sector continues to evolve rapidly, driven by sustained private equity investment, ongoing strategic consolidation, and increasing demand for integrated, full-service solutions.
Key sector takeaways for Q2 2026 include:
- Surge in add-on activity as platforms established in the 2024 resurgence continue to grow through M&A
- Continued shift towards full-service models across regulatory, HEOR, marketing and advertising, and medical affairs
- High volume of strategy consulting deals as demand for specialized services increases in line with development complexity
- Market headwinds include payor scrutiny, pricing pressure, and regulatory volatility
We hope this update provides a helpful resource for industry participants as they plan for the second half of the year. We can be reached at pharmacommercialization@providenthp.com if you’re interested in discussing the market in greater depth.
Provide your information below to access this document.
